

Local PI to be added in accordance with local laws and regulations

References


1. Fidler IJ, et al. *Proc Nat Acad Sci USA* 1981; 78: 1680-1684.
2. Murray JL, et al. *J Clin Oncol.* 1989;7:1915-1925.
3. Kleinerman ES, et al. *Cancer Immunol Immunother* 1992;34:211-220.
4. Meyers PA & Gorlick R. *Pediatr Clin North Am* 1997; 44: 973-989.
5. Nardin A, et al. *Curr Cancer Drug Targets* 2006; 6: 123-133.
6. Strober W, et al. *Nat Rev Immunol* 2006; 6: 9-20.
7. Mepact Summary of Product Characteristics.



Mepact tackles the primary threat to life in osteosarcoma

Mepact is an immunomodulator that specifically targets lung micro-metastases, the primary cause of death in osteosarcoma¹⁻⁴

Lipid bilayers form to create a stable liposomal structure which facilitates the entry of Mepact to phagocytic macrophages⁵




When Mepact comes into contact with macrophages in the lungs, the macrophage is stimulated to phagocytose the Mepact liposome⁵



Within the macrophage, Mepact is broken down, releasing MDP into the cytosol where it activates NOD2, resulting in the release of cytokines and tumour necrosis factor alpha^{6,7}



These cytokines have direct tumouricidal activity on lung micro-metastases. Activated macrophages also attach to the micro-metastases, further promoting the secretion of cytokines⁵



Mechanism of action